Grifols, S.A. is a Spanish multinational pharmaceutical and chemical manufacturer, primarily focused on producing blood plasma-based products[2]. Founded in 1940 by Dr. Josep A. Grífols Roig in Barcelona, the company has grown to become the European leader and largest worldwide producer in its field[2]. ## Key Facts - Headquarters: Barcelona, Spain - Founded: 1940 (origins dating back to 1909) - Listed on: Madrid Stock Exchange (since 2006) and IBEX 35 index (since 2008) - Main products: IVIG, albumin, Factor VIII, and other plasma-derived products[2] ## Operations Grifols operates globally with significant presence in: - Manufacturing: Plants in Parets del Vallès (Spain), Los Angeles, and Clayton, North Carolina - Plasma collection: 230 plasmapheresis centers in the United States, collecting about 5.8 million liters of plasma annually[2] ## Recent Developments - December 2024: Private equity firm Brookfield is nearing a potential takeover of Grifols, preparing to acquire a 65% controlling stake for approximately $11 per share, valuing the deal at around $7.4 billion[2] - Early 2024: Grifols faced allegations from short seller Gotham City Research, leading to significant market value loss and subsequent company denials of wrongdoing[2] Grifols continues to innovate in plasma-derived medicines and biopharmaceutical solutions, enabling millions of patients worldwide to lead more productive lives[3]. Citations: [1] https://www.grifols.com/en/home [2] https://en.wikipedia.org/wiki/Grifols [3] https://grifols.jobs [4] https://www.grifolsplasma.com/en/home [5] https://www.instagram.com/grifols_official/ [6] https://www.grifolsplasmadonorhub.com